A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Détails

ID Serval
serval:BIB_B22382CA0CC2
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.
Périodique
New England Journal of Medicine
Auteur(s)
Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Soelberg Sørensen P., Vermersch P., Chang P., Hamlett A., Musch B., Greenberg S.J.
Collaborateur(s)
CLARITY Study Group
Contributeur(s)
Giovannoni G., Comi G., Cook S., Rammohan K., Rieckmann P., Soelberg Sørensen P., Vermersch P., Sandberg-Wollheim M., Cuzick J., Juliusson G., Reingold S., King J., Pollard J., Sedal L., Aichner F., Eggers C., Dive D., Medaer R., Ferreira M., Manchev I., Milanov I., Haralanov L., Deleva N., Petrova N., Bozhinov P., Zahariev Z., Stamenov B., Shotekov P., Petrov I., Moskov R., Emond F., Freedman M., Grand'Maison F., Jacques F., Vorobeychik G., Demarin V., Kovacicek M., Lusic I., Perhat-Bucevic T., Havrdova E., Talab R., Kanovsky P., Soelberg Sørensen P., Petersen T., Gross-Paju K., Kalbe I., Toomsoo T., Elovaara I., Eralinna JP., Reunanen M., Clavelou P., Damier P., Debouverie M., Edan G., Gout O., Labauge P., Laplaud D., Wiertlewski S., Vermersch P., Heidenreich F., Mäurer M., Kieseier B., Limmroth V., Oschmann P., Schimrigk S., Steinbrecher A., Zettl U., Ziemann U., Karageorgiou K., Kyritsis A., Papadimitriou A., Amato MP., Bernardi G., Morra VB., Comi G., Galgani S., Gallo P., Patti F., Marrosu M., Pozzilli C., Trojano M., Mancardi GL., Gebeily S., Koussa S., Wehbe M., Yamout B., Vaitkus A., Metra M., Messouak O., Mossaddaq R., Slassi I., Yahyaoui M., Hupperts RM., Czlonkowska A., Kozubski W., Nyka W., Selmaj K., Szczudlik A., Figueiredo J., Pedrosa R., Alifirova V., Balyazin V., Barbarash O., Belova A., Boyko A., Gusev E., Elchaninov A., Jacoupov E., Julev N., Kotov S., Kudryavtsev A., Laskov V., Lesnyak O., Odinak M., Pasechnik E., Poverennonva I., Skoromets A., Spirin N., Stolyarov I., Vorobieva O., Voskresenskaya O., Zaslavskiy L., Zonova E., Bohlega S., El-Jumah M., Drulovic J., Nadj C., Goebels N., Schluep M., Ayed-Frih M., Hentati F., Mhiri C., Mrabet A., Mrissa R., Idiman E., Karabudak R., Turan OF., Ahmed F., Constantinescu C., Giovannoni G., Hawkins C., Palace J., Sharrack B., Loganovsky K., Moskovko S., Nehrych T., Voloshyna NP., Carlini W., Cook S., English J., Garmany G., Glyman S., Huddlestone J., Hurwitz B., Kresa-Reahl K., Mikol D., Pardo G., Rammohan K., Rao H., Reif M., Thrower B., Royal W., Webb R., Wynn D., Naga C., Allen N., Lin K., Stefoski D., Balabanov R.
ISSN
1533-4406 (Electronic)
ISSN-L
0028-4793
Statut éditorial
Publié
Date de publication
2010
Peer-reviewed
Oui
Volume
362
Numéro
5
Pages
416-426
Langue
anglais
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Résumé
BACKGROUND: Cladribine provides immunomodulation through selective targeting of lymphocyte subtypes. We report the results of a 96-week phase 3 trial of a short-course oral tablet therapy in patients with relapsing-remitting multiple sclerosis.
METHODS: We randomly assigned 1326 patients in an approximate 1:1:1 ratio to receive one of two cumulative doses of cladribine tablets (either 3.5 mg or 5.25 mg per kilogram of body weight) or matching placebo, given in two or four short courses for the first 48 weeks, then in two short courses starting at week 48 and week 52 (for a total of 8 to 20 days per year). The primary end point was the rate of relapse at 96 weeks.
RESULTS: Among patients who received cladribine tablets (either 3.5 mg or 5.25 mg per kilogram), there was a significantly lower annualized rate of relapse than in the placebo group (0.14 and 0.15, respectively, vs. 0.33; P<0.001 for both comparisons), a higher relapse-free rate (79.7% and 78.9%, respectively, vs. 60.9%; P<0.001 for both comparisons), a lower risk of 3-month sustained progression of disability (hazard ratio for the 3.5-mg group, 0.67; 95% confidence interval [CI], 0.48 to 0.93; P=0.02; and hazard ratio for the 5.25-mg group, 0.69; 95% CI, 0.49 to 0.96; P=0.03), and significant reductions in the brain lesion count on magnetic resonance imaging (MRI) (P<0.001 for all comparisons). Adverse events that were more frequent in the cladribine groups included lymphocytopenia (21.6% in the 3.5-mg group and 31.5% in the 5.25-mg group, vs. 1.8%) and herpes zoster (8 patients and 12 patients, respectively, vs. no patients).
CONCLUSIONS: Treatment with cladribine tablets significantly reduced relapse rates, the risk of disability progression, and MRI measures of disease activity at 96 weeks. The benefits need to be weighed against the risks. (ClinicalTrials.gov number, NCT00213135.)
Mots-clé
Administration, Oral, Adolescent, Adult, Aged, Analysis of Variance, Brain/pathology, Cladribine/adverse effects, Cladribine/therapeutic use, Disability Evaluation, Disease Progression, Double-Blind Method, Female, Herpes Zoster/etiology, Humans, Immunosuppressive Agents/adverse effects, Immunosuppressive Agents/therapeutic use, Intention to Treat Analysis, Lymphopenia/chemically induced, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting/drug therapy, Multiple Sclerosis, Relapsing-Remitting/pathology, Young Adult
Pubmed
Web of science
Création de la notice
30/01/2014 15:30
Dernière modification de la notice
20/08/2019 15:20
Données d'usage